BMRN
Price
$57.77
Change
+$1.02 (+1.80%)
Updated
Sep 5 closing price
Capitalization
11.09B
45 days until earnings call
DNTH
Price
$26.50
Change
+$1.84 (+7.46%)
Updated
Sep 5 closing price
Capitalization
852.99M
Interact to see
Advertisement

BMRN vs DNTH

Header iconBMRN vs DNTH Comparison
Open Charts BMRN vs DNTHBanner chart's image
BioMarin Pharmaceutical
Price$57.77
Change+$1.02 (+1.80%)
Volume$1.46M
Capitalization11.09B
Dianthus Therapeutics
Price$26.50
Change+$1.84 (+7.46%)
Volume$679.67K
Capitalization852.99M
BMRN vs DNTH Comparison Chart in %
Loading...
BMRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BMRN vs. DNTH commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMRN is a Hold and DNTH is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (BMRN: $57.77 vs. DNTH: $26.50)
Brand notoriety: BMRN and DNTH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BMRN: 76% vs. DNTH: 180%
Market capitalization -- BMRN: $11.09B vs. DNTH: $852.99M
BMRN [@Biotechnology] is valued at $11.09B. DNTH’s [@Biotechnology] market capitalization is $852.99M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMRN’s FA Score shows that 0 FA rating(s) are green whileDNTH’s FA Score has 0 green FA rating(s).

  • BMRN’s FA Score: 0 green, 5 red.
  • DNTH’s FA Score: 0 green, 5 red.
According to our system of comparison, DNTH is a better buy in the long-term than BMRN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMRN’s TA Score shows that 2 TA indicator(s) are bullish while DNTH’s TA Score has 5 bullish TA indicator(s).

  • BMRN’s TA Score: 2 bullish, 6 bearish.
  • DNTH’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, DNTH is a better buy in the short-term than BMRN.

Price Growth

BMRN (@Biotechnology) experienced а -0.86% price change this week, while DNTH (@Biotechnology) price change was +12.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

BMRN is expected to report earnings on Oct 22, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BMRN($11.1B) has a higher market cap than DNTH($853M). BMRN has higher P/E ratio than DNTH: BMRN (17.04) vs DNTH (3.24). DNTH YTD gains are higher at: 21.560 vs. BMRN (-12.110). BMRN has higher annual earnings (EBITDA): 934M vs. DNTH (-129.49M). BMRN has more cash in the bank: 1.43B vs. DNTH (257M). DNTH has less debt than BMRN: DNTH (1.33M) vs BMRN (604M). BMRN has higher revenues than DNTH: BMRN (3.06B) vs DNTH (4.85M).
BMRNDNTHBMRN / DNTH
Capitalization11.1B853M1,301%
EBITDA934M-129.49M-721%
Gain YTD-12.11021.560-56%
P/E Ratio17.043.24526%
Revenue3.06B4.85M63,123%
Total Cash1.43B257M557%
Total Debt604M1.33M45,414%
FUNDAMENTALS RATINGS
BMRN vs DNTH: Fundamental Ratings
BMRN
DNTH
OUTLOOK RATING
1..100
5841
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
57
Fair valued
PROFIT vs RISK RATING
1..100
10041
SMR RATING
1..100
6597
PRICE GROWTH RATING
1..100
6440
P/E GROWTH RATING
1..100
9964
SEASONALITY SCORE
1..100
5049

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BMRN's Valuation (54) in the Biotechnology industry is in the same range as DNTH (57) in the null industry. This means that BMRN’s stock grew similarly to DNTH’s over the last 12 months.

DNTH's Profit vs Risk Rating (41) in the null industry is somewhat better than the same rating for BMRN (100) in the Biotechnology industry. This means that DNTH’s stock grew somewhat faster than BMRN’s over the last 12 months.

BMRN's SMR Rating (65) in the Biotechnology industry is in the same range as DNTH (97) in the null industry. This means that BMRN’s stock grew similarly to DNTH’s over the last 12 months.

DNTH's Price Growth Rating (40) in the null industry is in the same range as BMRN (64) in the Biotechnology industry. This means that DNTH’s stock grew similarly to BMRN’s over the last 12 months.

DNTH's P/E Growth Rating (64) in the null industry is somewhat better than the same rating for BMRN (99) in the Biotechnology industry. This means that DNTH’s stock grew somewhat faster than BMRN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BMRNDNTH
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
71%
Bearish Trend 3 days ago
88%
Momentum
ODDS (%)
Bearish Trend 3 days ago
72%
Bullish Trend 3 days ago
77%
MACD
ODDS (%)
Bearish Trend 3 days ago
64%
Bullish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
57%
Bullish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
61%
Bullish Trend 3 days ago
79%
Advances
ODDS (%)
Bullish Trend 6 days ago
60%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
61%
Bearish Trend about 1 month ago
88%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
48%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
BMRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNTH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYBIX88.841.49
+1.71%
Rydex Basic Materials Inv
VRSGX29.78N/A
N/A
Virtus KAR Small-Cap Growth R6
ECOIX10.34N/A
N/A
Ecofin Global Renewables Infras Ins
ELGAX6.20N/A
N/A
Columbia Select Large Cap Growth A
BPTUX213.15N/A
N/A
Baron Partners R6

BMRN and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMRN has been loosely correlated with ITOS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if BMRN jumps, then ITOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMRN
1D Price
Change %
BMRN100%
+1.80%
ITOS - BMRN
49%
Loosely correlated
N/A
IBO - BMRN
42%
Loosely correlated
+3.81%
DNTH - BMRN
40%
Loosely correlated
+7.46%
SYRE - BMRN
40%
Loosely correlated
+0.06%
ABUS - BMRN
39%
Loosely correlated
+4.74%
More

DNTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNTH has been loosely correlated with IMNM. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if DNTH jumps, then IMNM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNTH
1D Price
Change %
DNTH100%
+7.46%
IMNM - DNTH
55%
Loosely correlated
+7.35%
OCUL - DNTH
51%
Loosely correlated
+7.09%
XNCR - DNTH
50%
Loosely correlated
+2.15%
CRNX - DNTH
50%
Loosely correlated
+3.97%
ERAS - DNTH
49%
Loosely correlated
+8.78%
More